LEI-105

LEI-105 is a potent, highly selective, and reversible dual DAGL-α/DAGL-β inhibitor with pIC50 pf 7.5/7.4 respectively; shows no activity against other enzymes involved in endocannabinoid metabolism (ABHD6, ABHD12, MAGL, or FAAH), and no affinity for CB1 receptor; concentration-dependently reduces 2-AG levels, but not anandamide levels, in Neuro2A cells; reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model.

References 1. Baggelaar MP, et al. J Am Chem Soc. 2015 Jul 15;137(27):8851-7. View Related Products by Target Diacylglycerol Lipase (DAGL)